Skip to main content
Psychedex

1Provenance card

the boundary, as counts

Sources

4235 with DOI

17 strong · 21 moderate · 4 weak

Compilations

22026-05-13T07:13:13.752Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

38last ruled 2026-06-04

16 awaiting a ruling

Issued documents

62026-10-19T20:30:43.786Z

notice · info card · emergency

Searches

360 with no results

queries and counts on the build

Claims checked

161109 supported

109 supported · 52 not

Correspondence

0received

consent field ships in Phase 4

Edges

492

derivations recorded for this entity

Complete over 42 sources, 2 compilations, and 38 decisions.Not here: the private journal (never); 16 proposals awaiting a ruling (listed as pending only).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/ayahuasca/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued emergency
  2. 2026-10-19issueIssued info_card
  3. 2026-10-19issueIssued notice
  4. 2026-09-07srcRegistered Clinical Trials of Ayahuasca and DMT: A Scoping Review
  5. 2026-09-07srcMetabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study
  6. 2026-09-07srcKinetic profile of N,N-dimethyltryptamine and beta-carbolines in saliva and serum after oral administration of ayahuasca
  7. 2026-09-07srcNeurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors
  8. 2026-09-07srcIncreased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant
  9. 2026-09-07srcLong-term ayahuasca use is associated with preserved global cognitive function and improved memory: a cross-sectional study with ritual users
  10. 2026-09-07srcDimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.
  11. 2026-09-07srcA possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity
  12. 2026-09-07srcExamining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: a factorial dose-escalation study
  13. 2026-09-07srcPopulation pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects
  14. 2026-09-07srcInhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans
  15. 2026-09-07srcEfficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis
  16. 2026-09-07srcValidation of an analytical method for the determination of the main ayahuasca active compounds
  17. 2026-09-07srcComposition, standardization and chemical profiling of Banisteriopsis caapi, a plant for the treatment of neurodegenerative disorders relevant to Parkinson's disease
  18. 2026-09-07srcDevelopments in harmine pharmacology--implications for ayahuasca use and drug-dependence treatment
  19. 2026-09-07srcPreliminary effects of ayahuasca on mental and physical health: A systematic review of prospective studies
  20. 2026-09-07srcEfficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis
  21. 2026-09-07srcMaternal and developmental toxicity of the hallucinogenic plant-based beverage ayahuasca in rats
  22. 2026-09-07srcRapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
  23. 2026-09-07srcAyahuasca: pharmacology, safety, and therapeutic effects
  24. 2026-09-07srcAcute experiences and persisting psychological effects of DMT-harmala alkaloid combination: phase 1 study
  25. 2026-09-07srcBeyond the Psychoactive Effects of Ayahuasca: Cultural and Pharmacological Relevance of Its Emetic and Purging Properties
  26. 2026-09-07srcEffects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans
  27. 2026-09-07srcPharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial
  28. 2026-09-07srcDevelopment of a physiologically based pharmacokinetic model of N,N-dimethyltryptamine, harmine, and their interactions from ayahuasca in rats and humans
  29. 2026-09-07srcAutonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine
  30. 2026-09-07srcAltered State of Consciousness and Mental Imagery as a Function of N,N-dimethyltryptamine Concentration in Ritualistic Ayahuasca Users
  31. 2026-09-07srcAyahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review
  32. 2026-09-07srcThe psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network
  33. 2026-09-07srcThe pharmacological interaction of compounds in ayahuasca: a systematic review
  34. 2026-09-07srcPredicting drug-drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling
  35. 2026-09-07srcThe Therapeutic Potentials of Ayahuasca: Possible Effects against Various Diseases of Civilization
  36. 2026-09-07srcPsychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
  37. 2026-09-07srcMolecular Pathways of the Therapeutic Effects of Ayahuasca
  38. 2026-09-07srcToxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact
  39. 2026-09-07srcHuman pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics
  40. 2026-09-07srcVarious alkaloid profiles in decoctions of Banisteriopsis caapi
  41. 2026-09-07srcMonoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca
  42. 2026-09-07srcBanisteriopsis caapi alkaloid concentrations - ResearchGate/Callaway data compilation
  43. 2026-09-07srcLegal status of ayahuasca by country - Wikipedia
  44. 2026-09-07srcPsychotria viridis DMT content in leaves
  45. 2026-09-07srcBanisteriopsis caapi - Plants of the World Online
  46. 2026-09-04issueIssued emergency
  47. 2026-09-04issueIssued info_card
  48. 2026-09-04issueIssued notice
  49. 2026-06-04proposal16 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  50. 2026-06-04publicationPublication — backfill
  51. 2026-05-13revisionRevision 3
  52. 2026-05-13genGeneration — pipeline-v5 · with 2 morepipeline-v5
  53. 2026-05-13rungeneration run
  54. 2026-04-26proposalcontraindication · other
  55. 2026-04-26proposalcontraindication · other
  56. 2026-04-26proposalcontraindication · hepatic
  57. 2026-04-26proposalcontraindication · cardiovascular
  58. 2026-04-26proposalcontraindication · psychiatric
  59. 2026-04-26proposalcontraindication · psychiatric
  60. 2026-04-26proposalcontraindication · pregnancy_breastfeeding
  61. 2026-04-26proposaltolerance
  62. 2026-04-26proposalwithdrawal
  63. 2026-04-26proposaldependence · full
  64. 2026-04-26proposaltoxicity
  65. 2026-04-26proposaldose_tier · heavy
  66. 2026-04-26proposaldose_tier · strong
  67. 2026-04-26proposaldose_tier · common
  68. 2026-04-26proposaldose_tier · light
  69. 2026-04-26proposaldose_tier · threshold
  70. 2026-04-26revisionRevision 2
  71. 2026-04-26genGeneration — pipeline-v5 · with 6 morepipeline-v5
  72. 2026-04-26rungeneration run
  73. 2026-03-17importImported from Curiosity v1
  74. 2026-03-17publicationPublication — backfill
  75. 2026-03-17revisionRevision 1

The same entries, as forms: six forms.